First indication
Dengue
A single-target test on the multiplex-ready cartridge, chosen as the leanest route through regulatory approval.
Cautana is developing a molecular testing platform that takes a fingerprick of blood to an answer inside the clinic, for the places where the nearest laboratory is a day’s travel away.
Made in Basel, Switzerland.
Fleming KA et al. The Lancet Commission on diagnostics. Lancet 2021;398:1997–2050.
Molecular tests such as RT-qPCR are the reference method for many infections. They are also built for centralised laboratories: expensive instruments, trained staff, a cold chain and reliable transport.
In distributed health systems, where patients often pay out of pocket, that model breaks down. Samples travel for days, results arrive after the patient has gone home, and doctors treat on suspicion instead of evidence.
Illustrative referral journeys from patient to result. Line lengths are scaled to distance.
Our platform is three modules that work together. Each is a single-use consumable, designed for clinic staff without laboratory training and for places without a laboratory’s infrastructure.
The first two modules are general-purpose tools and will reach the market first. The test cartridge follows once they are established.
Collect
A handheld, fully disposable device that collects a fingerprick blood sample with a standard lancet and built-in vacuum. No venous draw, no tubes to send away.
Prepare
Gets the sample ready for testing in a few simple hand steps, without pipettes, centrifuges or a power supply. Designed so that anyone in the clinic can use it.
Answer
A single-use RT-qPCR cartridge read by a compact benchtop reader. Built for multiplex panels, so a clinician can ask which infection a patient has, not only whether they have one.
Fever is one of the most common reasons to see a doctor, and one of the hardest to diagnose without a laboratory. Dengue, malaria, chikungunya and other infections look alike in the first days, yet need different treatment.
First indication
A single-target test on the multiplex-ready cartridge, chosen as the leanest route through regulatory approval.
Flagship panel
One blood sample tested for the common causes of acute fever in our markets, to replace empiric treatment with a diagnosis.
Planned
Strain-level HPV identification from cervical swabs, to support risk-based cervical cancer screening.
We begin where the gap is widest: distributed, price-sensitive health systems with a high burden of infectious disease and diagnostics paid out of pocket.
Regulatory status. Cautana’s products are in development. They have not been cleared or approved by any regulatory authority and are not available for sale.